NKTR-118 Clinical Trial Of Opioid-Bowel Dysfunction Treatment Is Successful

Armen Hareyan's picture
Advertisement

Nektar Therapeutics presented positive results from Phase 1 and preclinical studies of NKTR-118 (oral PEG-naloxol) at the American Academy of Pain Management (AAPM) meeting in Las Vegas, Nevada. NKTR-118 is Nektar's proprietary oral therapy being studied for its potential to treat patients suffering from opioid-bowel dysfunction (OBD), including opioid-induced constipation (OIC).

Advertisement